Breaking Down Barriers to Access and Affordability of Specialty and Rare-Disease Treatments

By Dea Belazi, AscellaHealth

Successfully achieving a primary endpoint in a rare-disease trial is a significant milestone for biopharmaceutical research teams. After years of investigation and meticulous clinical trials, it is natural for organizations to believe that the hardest part is behind them. However, developers working to improve clinical outcomes and quality of life for patients with debilitating rare conditions soon face a new challenge: overcoming the barriers to treatment access.

To read more, click here